Hepatocellular

FORT LEE, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., and a fully integrated biopharmaceutical company dedicated to…

New York, USA, June 26, 2023 (GLOBE NEWSWIRE) -- Hepatocellular Carcinoma Clinical Trial Analysis: DelveInsight Evaluates a Robust Pipeline as 90+ Influential Pharma Players to Set Foot…

<!-- Name:DistributionId Value:8827692 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

SYDNEY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research Published Latest Hepatocellular Carcinoma Drugs Market Study with an in-depth analysis of the current scenario, the…

MedPage Today brought together three leaders in the field of liver cancer to discuss the latest research…

MedPage Today brought together three leaders in the field of liver cancer to discuss the latest research…

MedPage Today brought together three leaders in the field to discuss the latest research and clinical…

SALT LAKE CITY, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for…

Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a…

WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based…